Clal Insurance Enterprises Holdings Ltd Acquires New Position in MediWound Ltd. $MDWD

Clal Insurance Enterprises Holdings Ltd bought a new position in shares of MediWound Ltd. (NASDAQ:MDWD) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 57,804 shares of the biopharmaceutical company’s stock, valued at approximately $1,042,000. Clal Insurance Enterprises Holdings Ltd owned approximately 0.52% of MediWound at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in MDWD. Meitav Investment House Ltd. increased its position in shares of MediWound by 825.7% during the third quarter. Meitav Investment House Ltd. now owns 291,618 shares of the biopharmaceutical company’s stock worth $5,241,000 after purchasing an additional 260,116 shares in the last quarter. Silverberg Bernstein Capital Management LLC increased its position in MediWound by 17.1% during the 3rd quarter. Silverberg Bernstein Capital Management LLC now owns 172,816 shares of the biopharmaceutical company’s stock valued at $3,114,000 after buying an additional 25,281 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in MediWound by 104.4% in the second quarter. The Manufacturers Life Insurance Company now owns 26,062 shares of the biopharmaceutical company’s stock valued at $505,000 after buying an additional 13,312 shares during the last quarter. MGO One Seven LLC boosted its holdings in MediWound by 82.6% in the third quarter. MGO One Seven LLC now owns 22,209 shares of the biopharmaceutical company’s stock worth $400,000 after acquiring an additional 10,047 shares in the last quarter. Finally, Sheets Smith Investment Management acquired a new stake in MediWound in the third quarter worth about $362,000. 46.83% of the stock is currently owned by hedge funds and other institutional investors.

MediWound Price Performance

Shares of MDWD opened at $17.30 on Friday. MediWound Ltd. has a 1-year low of $14.14 and a 1-year high of $22.50. The firm has a 50-day simple moving average of $17.84 and a two-hundred day simple moving average of $17.90. The stock has a market cap of $221.61 million, a PE ratio of -9.11 and a beta of 0.13.

Wall Street Analysts Forecast Growth

MDWD has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price objective (up from $31.00) on shares of MediWound in a research report on Friday, November 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a report on Thursday, January 22nd. Zacks Research raised MediWound from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Finally, Wall Street Zen upgraded MediWound from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, MediWound presently has an average rating of “Hold” and a consensus target price of $31.67.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.